HOME >> MEDICINE >> NEWS
NIAID forms network to tackle potentially fatal reaction to smallpox vaccine

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today launched the Atopic Dermatitis and Vaccinia Network (ADVN), a nationwide research group that seeks to reduce the risk of eczema vaccinatum (EV), a severe and potentially deadly complication of smallpox immunization. EV occurs almost exclusively in people with a history of atopic dermatitis (AD), a chronic, itchy skin condition commonly referred to as eczema. While uncommon, EV can develop when AD patients are given the smallpox vaccine or come into close personal contact with people who recently received the vaccine. If untreated, EV can kill between 1 to 6 percent of those affected. In children younger than 2 years of age, EV has been estimated to kill up to 30 percent.

"Millions of Americans have a history of atopic dermatitis," says Anthony S. Fauci, M.D., director of NIAID. "Launching this network is an important step toward our goal of helping to protect everyone against the smallpox virus without the risk of life-threatening complications."

"Previous studies suggest that both innate and adaptive immunity are impaired in patients with atopic dermatitis, but the specific defects that increase the likelihood of eczema vaccinatum have yet to be explained," says Daniel Rotrosen, M.D., director of NIAID's Division of Allergy, Immunology and Transplantation. "The information generated by this network will improve our understanding of the immune responses of these patients and should greatly influence the design of a safer smallpox vaccine."

The ADVN comprises three integrated components: a clinical studies consortium, an animal studies consortium and a statistical and data coordinating center.

The ADVN Clinical Studies Consortium will, among other activities, seek to understand why people with AD have such severe reactions to smallpox vaccine by evaluating their immune responses after natural exposure to less harmf
'"/>

Contact: Paul Williams
pwilliams@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
19-May-2004


Page: 1 2

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID launches program to improve medical tools against emerging infectious diseases
8. NIAID rotavirus vaccine licensed for commercialization
9. Second NIAID SARS vaccine candidate helps mice fend off SARS
10. NIAID vaccine protects against SARS virus infection in mice
11. NIAID Ebola vaccine enters human trial

Post Your Comments:
(Date:5/28/2015)... Hexagon Geospatial is pleased to announce that ... engineering, spatial data and mapping services, is using Hexagon ... clouds for urban change assessments in Bernalillo County, New ... Spatial Data Division implemented a countywide approach to generating ... by a variety of different digital aerial camera systems, ...
(Date:5/28/2015)... May 28, 2015 lifeIMAGE ... round of financing led by Cambia Health Solutions ... dedicated to transforming health care by creating a person-focused ... most utilized network for exchanging medical imaging, will use ... base, increase the breadth of its network capabilities and ...
(Date:5/28/2015)... 28, 2015 WebWatcher, the ... their partnership with BeSure Consulting to help ... The partnership will combine BeSure Consulting’s ... parental monitoring software solution. , Led by ... Consulting's passion is concentrated on teaching law ...
(Date:5/28/2015)... PA (PRWEB) May 28, 2015 A ... and adventures. Each item on the bucket ... impossible events, experiences and tasks that the owner wants ... no right or wrong when it comes to making ... a business, writing poems, publishing a book, seeing the ...
(Date:5/28/2015)... Ask not what your racquet can do for you ... your racquet. With the launch of their new digital campaign, ... astonishing tricks and unique skill to HEAD Pro Players and ... trick artist playfully demonstrates how to gain more control over ... but also challenges tennis enthusiasts everywhere to join the show. ...
Breaking Medicine News(10 mins):Health News:Hexagon Geospatial Supports Urban Change Detection Programs in New Mexico 2Health News:Hexagon Geospatial Supports Urban Change Detection Programs in New Mexico 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 4Health News:WebWatcher Partners with BeSure Consulting 2Health News:WebWatcher Partners with BeSure Consulting 3Health News:Tennis Artist Baffles Novak Djokovic - HEAD Launches Trick Shot Campaign “Frame & Play” 2
(Date:5/28/2015)...  Pharmaceutic Labs announces its official status as ... the FDA,s Drug Quality and Security Act. To ... to Current Good Manufacturing Practice (CGMP) and increased ... highest standards of CGMP 21 CFR Part 210 ... with FDA regulations and ensure patient safety, Pharmaceutic ...
(Date:5/28/2015)... INDIANAPOLIS , May 28, 2015  Eli ... final results of the Phase III PROCLAIM trial ... presentation at the American Society of Clinical Oncology ... . PROCLAIM was a randomized, Phase III superiority ... lung cancer (NSCLC), which evaluated Lilly,s ALIMTA ® ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/rjpc7h/2015_strategies ) has ... in the US Ancillary Hospital Locations (ERs, ORs, ... offering. This new 973-page report contains ... diagnostic testing markets outside the main hospital laboratory ... of the market dynamics, size, growth, regulatory requirements, ...
Breaking Medicine Technology:PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 2PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 3PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 4PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 5PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 6PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 7PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 8Strategies in the US Ancillary Hospital Locations (ERs, ORs, ICUs) Diagnostic Testing Market 2015-2020 2
Cached News: